Stocktoria
Sunshine Biopharma Inc. SBFM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2008-08-15
Sunshine Biopharma Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 33.8% | 30.6% | 34.6% | 39.0% | 48.4% |
| Operating margin | -17.2% | -16.7% | -19.9% | -621.3% | -1068.2% |
| Net margin | -16.5% | -14.7% | -18.7% | -615.4% | -5444.4% |
| FCF margin | -15.2% | -40.7% | -36.8% | -125.2% | -800.8% |
| Return on assets | -19.9% | -16.8% | -16.5% | -91.5% | -564.6% |
| Return on equity | -25.9% | -21.8% | -21.2% | -123.7% | -5875.6% |
| Current ratio | 4.17 | 4.11 | 4.48 | 3.94 | 24.07 |
| Revenue growth | 4.1% | 44.7% | 454.4% | 1802.4% | 219.9% |
Source: SEC EDGAR filings · CIK 0001402328 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.